Skip to main content
SpringerLink
Log in

Dapagliflozin administration for 1 year promoted kidney enlargement in patient with ADPKD

  • Case Report
  • Published:
CEN Case Reports Aims and scope Submit manuscript

Abstract

To date, there is insufficient evidence regarding use of sodium–glucose cotransporter-2 (SGLT2) inhibitors for patients with autosomal-dominant polycystic kidney disease (ADPKD), as such cases have been excluded from previous clinical trials exploring the kidney protection effects of such medications. Here, findings of an ADPKD patient who received dapagliflozin, a selective SGLT2 inhibitor, for 1 year are presented. A 38-year-old woman with a family history of ADPKD wished for treatment with dapagliflozin. After starting administration at 10 mg/day, total kidney volume (TKV) continued to increase, from 1641 to 1764 mL after 84 days and then to 2297 mL after 340 days. The estimated glomerular filtration rate (eGFR) was also decreased from 67.3 to 56.2 mL/min/1.73 m2, and then to 51.4 mL/min/1.73 m2 at those times. Immediately after discontinuation of dapagliflozin, TKV and eGFR were slightly improved to 2263 mL and 55.1 mL/min/1.73 m2, respectively. Following a review of basic research studies, we consider that increased intratubular urinary osmotic pressure, compensatory glucose reabsorption by sodium–glucose cotransporter-1 in the late proximal tubule, and hypertrophy shown in collected cells caused by increased vasopressin may be associated with ADPKD disease progression. Caution may be needed when administering dapagliflozin to patients with ADPKD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287–301. https://doi.org/10.1016/S0140-6736(07)60601-1.

    Article  PubMed  Google Scholar 

  2. Ong AC, Devuyst O, Knebelmann B, Walz G, Diseases E-EWGfIK. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet. 2015;385(9981):1993–2002. https://doi.org/10.1016/S0140-6736(15)60907-2.

    Article  PubMed  Google Scholar 

  3. Dachy A, Decuypere JP, Vennekens R, Jouret F, Mekahli D. Is autosomal dominant polycystic kidney disease an early sweet disease? Pediatr Nephrol. 2022;37(9):1945–55. https://doi.org/10.1007/s00467-021-05406-z.

    Article  PubMed  Google Scholar 

  4. Nowak KL, Hopp K. Metabolic reprogramming in autosomal dominant polycystic kidney disease: evidence and therapeutic potential. Clin J Am Soc Nephrol. 2020;15(4):577–84. https://doi.org/10.2215/CJN.13291019.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Warner G, Hein KZ, Nin V, Edwards M, Chini CC, Hopp K, et al. Food restriction ameliorates the development of polycystic kidney disease. J Am Soc Nephrol. 2016;27(5):1437–47. https://doi.org/10.1681/ASN.2015020132.

    Article  CAS  PubMed  Google Scholar 

  6. Kipp KR, Rezaei M, Lin L, Dewey EC, Weimbs T. A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease. Am J Physiol Renal Physiol. 2016;310(8):F726–31. https://doi.org/10.1152/ajprenal.00551.2015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Torres JA, Kruger S, Broderick C, Amarlkhagva T, Agrawal S, Dodam JR, et al. Ketosis ameliorates renal cyst growth in polycystic kidney disease. Cell Metab. 2019;30(6):1007–23. https://doi.org/10.1016/j.cmet.2019.09.012.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Nowak KL, Steele C, Gitomer B, Wang W, Ouyang J, Chonchol MB. Overweight and obesity and progression of ADPKD. Clin J Am Soc Nephrol. 2021;16(6):908–15. https://doi.org/10.2215/CJN.16871020.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Hopp K, Catenacci VA, Dwivedi N, Kline TL, Wang W, You Z, et al. Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease. iScience. 2022;25(1):103697. https://doi.org/10.1016/j.isci.2021.103697.

    Article  CAS  PubMed  Google Scholar 

  10. Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46. https://doi.org/10.1056/NEJMoa2024816.

    Article  CAS  PubMed  Google Scholar 

  11. The E-KCG, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–27. https://doi.org/10.1056/NEJMoa2204233.

    Article  Google Scholar 

  12. Morioka F, Nakatani S, Uedono H, Tsuda A, Mori K, Emoto M. Short-term dapagliflozin administration in autosomal dominant polycystic kidney disease—a retrospective single-arm case series study. J Clin Med. 2023;12(19):6341. https://doi.org/10.3390/jcm12196341.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26(1):160–72. https://doi.org/10.1681/ASN.2013101138.

    Article  CAS  PubMed  Google Scholar 

  14. Kapoor S, Rodriguez D, Riwanto M, Edenhofer I, Segerer S, Mitchell K, et al. Effect of sodium-glucose cotransport inhibition on polycystic kidney disease progression in PCK rats. PLoS ONE. 2015;10(4): e0125603. https://doi.org/10.1371/journal.pone.0125603.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Li SR, Gulieva RE, Helms L, Cruz NM, Vincent T, Fu H, et al. Glucose absorption drives cystogenesis in a human organoid-on-chip model of polycystic kidney disease. Nat Commun. 2022;13(1):7918. https://doi.org/10.1038/s41467-022-35537-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Devuyst O, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD, Torres VE, et al. Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial. J Am Soc Nephrol. 2017;28(5):1592–602. https://doi.org/10.1681/ASN.2016040448.

    Article  CAS  PubMed  Google Scholar 

  17. Wang X, Zhang S, Liu Y, Spichtig D, Kapoor S, Koepsell H, et al. Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats. Kidney Int. 2013;84(5):962–8. https://doi.org/10.1038/ki.2013.199.

    Article  CAS  PubMed  Google Scholar 

  18. Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010;70(4):377–85. https://doi.org/10.2165/11318680-000000000-00000.

    Article  CAS  PubMed  Google Scholar 

  19. Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol. 2014;306(2):F188–93. https://doi.org/10.1152/ajprenal.00518.2013.

    Article  CAS  PubMed  Google Scholar 

  20. Sinha F, Federlein A, Biesold A, Schwarzfischer M, Krieger K, Schweda F, et al. Empagliflozin increases kidney weight due to increased cell size in the proximal tubule S3 segment and the collecting duct. Front Pharmacol. 2023;14:1118358. https://doi.org/10.3389/fphar.2023.1118358.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2008;19(1):102–8. https://doi.org/10.1681/ASN.2007060688.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Watanabe S, Sawa N, Mizuno H, Yamanouchi M, Suwabe T, Hoshino J, et al. Development of osmotic vacuolization of proximal tubular epithelial cells following treatment with sodium-glucose transport protein 2 inhibitors in type II diabetes mellitus patients-3 case reports. CEN Case Rep. 2021;10(4):563–9. https://doi.org/10.1007/s13730-021-00609-7.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1730–5. https://doi.org/10.2337/dc15-0355.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Perkins BA, Cherney DZ, Partridge H, Soleymanlou N, Tschirhart H, Zinman B, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014;37(5):1480–3. https://doi.org/10.2337/dc13-2338.

    Article  PubMed  Google Scholar 

  25. Takata T, Isomoto H. Pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: renoprotective mechanisms beyond glycemic control. Int J Mol Sci. 2021;22(9):4374. https://doi.org/10.3390/ijms22094374.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan

    Shinya Nakatani, Hideki Uedono, Akihiro Tsuda & Masanori Emoto

  2. Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan

    Fumiyuki Morioka

  3. Department of Nephrology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan

    Katsuhito Mori & Masanori Emoto

Authors
  1. Shinya Nakatani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fumiyuki Morioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hideki Uedono
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akihiro Tsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Katsuhito Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masanori Emoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shinya Nakatani.

Ethics declarations

Conflict of interest

None of the authors have conflicts of interests to declare in regard to dapagliflozin. Regarding SGLT2 inhibitors other than dapagliflozin, KM has received honorariums for lecturing from Mitsubishi Tanabe Pharma Corporation, AstraZeneca K.K., and Nippon Boehringer Ingelheim. KM and ME have received research funding from Tanabe Pharma Corporation.

Ethical approval

This article does not contain results of any studies with human participants or animals performed by any of the authors.

Informed consent

Written informed consent was obtained from the patient for publication of her clinical data.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakatani, S., Morioka, F., Uedono, H. et al. Dapagliflozin administration for 1 year promoted kidney enlargement in patient with ADPKD. CEN Case Rep (2023). https://doi.org/10.1007/s13730-023-00840-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13730-023-00840-4

Keywords

Search

Navigation